ACR open rheumatology最新文献

{"title":"Clinical Images: Flail elbows: destructive calcium pyrophosphate crystal arthritis.","authors":"Steven Szlembarski, Kari Falaas, Elie Gertner","doi":"10.1002/acr2.70020","DOIUrl":"10.1002/acr2.70020","url":null,"abstract":"","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 3","pages":"e70020"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RheuMetric Physician 0 to 10 Estimates of Inflammation, Damage, and Patient Distress at Initial Versus Follow-Up Visits in Contemporary Rheumatology Care.","authors":"Juan Schmukler, Tengfei Li, Joel A Block, Theodore Pincus","doi":"10.1002/acr2.70010","DOIUrl":"10.1002/acr2.70010","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to analyze the RheuMetric physician 0 to 10 visual numeric subscale (VNS) estimates of inflammatory activity (DOCINF), organ damage (DOCDAM), and patient distress (DOCDIS) at initial and follow-up routine rheumatology visits for possible incremental information to clarify physician estimate of global assessment (DOCGL).</p><p><strong>Methods: </strong>A retrospective cross-sectional study compared mean DOCGL, DOCINF, DOCDAM, and DOCDIS and the percentage contributed by inflammation, damage, and distress to DOCGL (total = 100%) at initial and follow-up visits in 563 unselected routine care patients, classified into four diagnosis categories: inflammatory (rheumatoid arthritis, systemic lupus erythematosus [SLE], spondylarthritis, vasculitis, and gout), primary osteoarthritis (OA), primary fibromyalgia (FM), and \"other\" diagnoses. Differences between initial and follow-up visits were estimated using t-tests.</p><p><strong>Results: </strong>In all patients, mean DOCGL was 4.0/10, DOCINF 1.6/10, DOCDAM 2.9/10, and DOCDIS 2.4/10, indicating higher estimates for damage and distress than for inflammation, including in all inflammatory diagnoses other than SLE. Highest mean estimates were 2.2 for DOCINF in inflammatory diagnoses, 4.9 for DOCDAM in primary OA, 6.3 for DOCDIS in primary FM. However, DOCDAM was 2.8 (0.6 uniyts higher than DOCINF) in inflammatory diagnoses. RheuMetric estimates of inflammation were significantly higher at initial than at follow-up visits, and estimates of damage were significantly lower at initial than at follow-up visits in all patients and in those with inflammatory diagnoses. DOCGL did not differ significantly at initial versus follow-up visits.</p><p><strong>Conclusion: </strong>DOCINF, DOCDAM, and DOCDIS add feasibly recorded, clinically relevant incremental information to DOCGL. Despite excellent contemporary control of inflammation, joint damage and patient distress remain important clinical problems in contemporary routine rheumatology care, documented by quantitative RheuMetric estimates.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 3","pages":"e70010"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applications of Artificial Intelligence in Vasculitides: A Systematic Review.","authors":"Mahmud Omar, Reem Agbareia, Mohammad E Naffaa, Abdulla Watad, Benjamin S Glicksberg, Girish N Nadkarni, Eyal Klang","doi":"10.1002/acr2.70016","DOIUrl":"10.1002/acr2.70016","url":null,"abstract":"<p><strong>Objective: </strong>Vasculitides are rare inflammatory disorders that sometimes can be difficult to diagnose due to their diverse presentations. This review examines the use of artificial intelligence (AI) to improve diagnosis and outcome prediction in vasculitis.</p><p><strong>Methods: </strong>A systematic search of PubMed, Embase, Web of Science, Institute of Electrical and Electronics Engineers Xplore, and Scopus identified relevant studies from 2000 to 2024. AI applications were categorized by data type (clinical, imaging, textual) and by task (diagnosis or prediction). Studies were assessed for risk of bias using the Prediction Model Risk of Bias Assessment Tool and Quality Assessment of Diagnostic Accuracy Studies-2.</p><p><strong>Results: </strong>A total of 46 studies were included. AI models achieved high diagnostic performance in Kawasaki disease, with sensitivities up to 92.5% and specificities up to 97.3%. Predictive models for complications, such as intravenous Ig resistance in Kawasaki disease, showed areas under the curves between 0.716 and 0.834. Other vasculitis types, especially those using imaging data, were less studied and often limited by small datasets.</p><p><strong>Conclusion: </strong>The current literature shows that AI algorithms can enhance vasculitis diagnosis and prediction, with deep- and machine-learning models showing promise in Kawasaki disease. However, broader datasets, more external validation, and the integration of newer models like large language models are needed to advance their clinical applicability across different vasculitis types.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 3","pages":"e70016"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Management of Lupus-Associated Autoimmune Myelofibrosis with Tofacitinib: A Case Report.","authors":"Hamidreza Soltani, Ali Dehghan","doi":"10.1002/acr2.70017","DOIUrl":"10.1002/acr2.70017","url":null,"abstract":"<p><p>We report a case of a 34-year-old woman with systemic lupus erythematosus (SLE) who developed thrombocytopenia and was diagnosed with lupus-associated autoimmune myelofibrosis. She was treated with hydroxychloroquine, tofacitinib (5 mg twice daily), intravenous Ig, and prednisone (5 mg twice daily, tapered to 5 mg daily after one month). After 10 months of this regimen, her bone marrow showed complete resolution of myelofibrosis. This case highlights the effectiveness of tofacitinib in the treatment of autoimmune myelofibrosis associated with SLE.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 3","pages":"e70017"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Long-Term Glucocorticoid Use Among Older Adults After New Diagnosis of Late-Onset Rheumatoid Arthritis.","authors":"Jiha Lee, Jonathan Martindale, Beth I Wallace, Namrata Singh, Una E Makris, Julie P W Bynum","doi":"10.1002/acr2.70013","DOIUrl":"10.1002/acr2.70013","url":null,"abstract":"<p><strong>Background: </strong>We evaluated changes in long-term glucocorticoid (GC) use and factors associated with persistent GC use in older adults with late-onset rheumatoid arthritis (LORA).</p><p><strong>Methods: </strong>Using 20% Medicare data from 2008 to 2017, we identified adults ≥66 years with a new diagnosis of LORA, disease-modifying antirheumatic drug (DMARD) use or at least two rheumatologist visits, and at least 12 months of follow-up data. Older adults were categorized as DMARD-exposed or DMARD-unexposed based on treatment during the 12 months after LORA diagnosis (index date). For each quarter after the index date, long-term GC use was defined as having oral GC prescriptions for at least 30 days with a dose >5 mg/day prednisone equivalent. We compared long-term GC use between quarter (Q)1 and Q4 and performed stratified mixed-effects logistic regression for factors associated with persistent GC use, defined as long-term GC use in Q2 to Q4.</p><p><strong>Results: </strong>The cohort included 15,425 individuals with two-thirds (62.5%) being DMARD-exposed. Between Q1 and Q4, the proportion of older adults on long-term GC declined from 44.1 to 24.9% (∆19.2%) among the DMARD-exposed and from 25.8 to 17.9% (∆7.9%) among the DMARD-unexposed. One year after the index date, 13.5% of the DMARD-exposed and 9.8% of the DMARD-unexposed were persistent GC users. In stratified mixed-effects logistic models, persistent GC use was associated with low-income subsidy status among the DMARD-exposed and with greater comorbidity burden among DMARD-unexposed.</p><p><strong>Conclusion: </strong>Long-term GC use declined more among DMARD-exposed than DMARD-unexposed patients. One in seven DMARD-exposed and one in ten DMARD-unexposed have persistent GC use which is associated with financial barriers and multimorbidity that may limit the use of steroid-sparing DMARDs.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 3","pages":"e70013"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Failure to Close: An Unexpected Surgical Complication Reveals OTULIN Haploinsufficiency.","authors":"Jessica Nguyen, Charlotte F Kim, Andrea A Ramirez, Tiphanie P Vogel","doi":"10.1002/acr2.11800","DOIUrl":"10.1002/acr2.11800","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this report is to raise awareness of a rare inborn error of immunity (IEI) that can predispose to inflammatory disease and infection risk by describing a patient case.</p><p><strong>Methods: </strong>We reviewed clinical findings, laboratory and pathology evaluations, and genetic results.</p><p><strong>Results: </strong>A 13-year-old female patient with a history of prematurity and spastic diplegic cerebral palsy underwent planned orthopedic procedures to correct chronic gait abnormalities. Her postoperative course was complicated by fevers associated with respiratory failure and wound dehiscence at the surgical sites. A chest computed tomography scan revealed bilateral consolidative pneumonia with parapneumonic effusions. Infectious and clinical immune evaluations were unremarkable. She had resolution of fevers and respiratory failure with broad-spectrum antibiotics; however, her wounds became progressively ulcerative and necrotic. A skin biopsy demonstrated skin ulceration with acute neutrophilic inflammation. She was started on glucocorticoids and infliximab infusions with prompt improvement in wound healing. Subsequently, a clinical genetic panel revealed a heterozygous variant in OTULIN c.787C>T, p.Arg263Trp, located at the same amino acid previously reported in OTULIN haploinsufficiency. OTULIN haploinsufficiency is a rare IEI that predisposes to life-threatening necrosis of the skin and lungs, often in response to Staphylococcus aureus infection.</p><p><strong>Conclusion: </strong>OTULIN haploinsufficiency predisposes to increased susceptibility to infections and tissue-specific necrosis often triggered by infection. Recognition of this rare IEI is important because patients with OTULIN haploinsufficiency may require combined antibiotic and immunomodulatory therapy.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 3","pages":"e11800"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143627097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-Depth Analysis of Disease Manifestations in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides Identifies Distinct Clinical Phenotypes.","authors":"Hanna Lindberg, Ann Knight, Erik Hellbacher, Olof Norling, Ewa Berglin, Bernd Stegmayr, Bo Baslund, Øyvind Palm, Hilde Haukeland, Iva Gunnarsson, Annette Bruchfeld, Maria Weiner, Per Eriksson, Mårten Segelmark, Sophie Ohlsson, Aladdin J Mohammad, Anna Svärd, Rille Pullerits, Hans Herlitz, Annika Söderbergh, Solbritt Rantapää-Dahlqvist, Johanna Dahlqvist","doi":"10.1002/acr2.70009","DOIUrl":"10.1002/acr2.70009","url":null,"abstract":"<p><strong>Objective: </strong>The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides are heterogeneous disorders. The aim of this study was to identify and characterize subgroups of patients based on sex, ANCA, age at diagnosis, and organ involvement.</p><p><strong>Methods: </strong>In total, 1,167 patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) were retrospectively recruited to the study. Data including cumulative involvement of 10 different organ systems, end-stage kidney disease (ESKD), sex, proteinase (PR) 3-ANCA, myeloperoxidase (MPO)-ANCA, age at diagnosis, disease duration, and relapse were obtained from medical records. Clinical variables were analyzed for associations with sex, age at diagnosis, and relapse using logistic regression analysis. Thirteen clinical variables were included in hierarchical cluster analyses using the Ward method.</p><p><strong>Results: </strong>In patients with GPA, PR3-ANCA, renal and pulmonary involvement, and ESKD were significantly associated with male sex, whereas MPO-ANCA was associated with female sex. Patients with GPA who were younger than 32 years of age at diagnosis were significantly more often females and had more ear-nose-throat involvement than patients older than 32 years. In patients with MPA, female patients were significantly younger at diagnosis than male patients. Relapse was significantly associated with young age at diagnosis and pulmonary involvement in GPA and with musculoskeletal involvement in MPA. Hierarchical cluster analyses identified five and seven patient clusters among individuals with GPA and MPA, respectively. PR3-/MPO-ANCA defined the largest clusters, whereas heart, gastrointestinal, and central nervous system involvement were hallmarks for three clusters for both patients with GPA and MPA.</p><p><strong>Conclusion: </strong>Sex, age at diagnosis, and specific organ involvements define clinically relevant subgroups among patients with ANCA-associated vasculitides.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 3","pages":"e70009"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Images: Multiple blisters on the upper and lower extremities in granulomatosis with polyangiitis.","authors":"Tokio Katakura, Tsuyoshi Shirai, Hiroshi Fujii, Kenta Oka, Yoshihide Asano","doi":"10.1002/acr2.70031","DOIUrl":"10.1002/acr2.70031","url":null,"abstract":"","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 3","pages":"e70031"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143677456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Pilot Testing of a Patient-Centered Reproductive Decision Aid for Pregnancy-Capable People With Rheumatic Diseases.","authors":"Mehret Birru Talabi, Megan E B Clowse, Kaleab Abebe, Susan J Blalock, Lisa S Callegari, Traci M Kazmerski, Raelynn O'Leary, Ashley Deal, Catherine Wright, Leslie E Pierce, Olivia M Stransky, Goutham Lakkaraju, Swetha Jasti, Sonya Borrero","doi":"10.1002/acr2.11791","DOIUrl":"10.1002/acr2.11791","url":null,"abstract":"<p><strong>Objective: </strong>Although women with rheumatic and musculoskeletal diseases (RMDs) are at an elevated risk for adverse pregnancy and perinatal outcomes, some report that they lack access to resources that support informed reproductive decision-making. We developed MyVoice:Rheum, a web-based decision aid to support women with RMDs in reproductive decision-making. We conducted a pilot trial to assess feasibility and acceptability of MyVoice:Rheum and to assess its preliminary effectiveness compared to a freely available online pamphlet about reproductive and RMDs.</p><p><strong>Methods: </strong>Using a parallel-arm randomized pilot trial design, we assigned women aged 18 to 44 years with RMDs in a 3:1 ratio to receive either MyVoice:Rheum or the control pamphlet immediately before a rheumatology clinical encounter. Quantitative and qualitative measures of feasibility, acceptability, and usability were assessed among MyVoice:Rheum users. We evaluated the preliminary effectiveness of MyVoice:Rheum in prompting family planning discussions as compared to pamphlet users, as well as its effects on users' reproductive knowledge and/or communication self-efficacy with rheumatologists.</p><p><strong>Results: </strong>We enrolled MyVoice:Rheum users (n = 31) and controls (n = 9) in the pilot study. MyVoice:Rheum users scored the tool as feasible, acceptable, and easy to use. Approximately 61% of MyVoice:Rheum users and 44% of controls had family planning discussions with their rheumatologists. MyVoice:Rheum users demonstrated increases in self-efficacy and knowledge scores after the intervention.</p><p><strong>Conclusion: </strong>In pilot testing, MyVoice:Rheum was feasible, acceptable, and usable to women with RMDs. Preliminary findings suggest that MyVoice:Rheum may increase family planning discussions in the rheumatology context and augment patients' reproductive knowledge and self-efficacy; these findings should be confirmed in a future full-scale study.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 3","pages":"e11791"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitochondrial-Mediated Platelet Activation in Polymyalgia Rheumatica.","authors":"Despina Michailidou, Linda Johansson, Jorge Armando Gonzalez Chapa, Ting Wang, Junmei Chen, José A López, Solbritt Rantapää-Dahlqvist, Christian Lood","doi":"10.1002/acr2.70021","DOIUrl":"10.1002/acr2.70021","url":null,"abstract":"<p><strong>Objective: </strong>Platelet activation is thought to participate in polymyalgia rheumatica (PMR) pathogenesis. Upon platelet activation, mitochondria are expelled into the extracellular space. However, whether extracellular mitochondria are present in patients with PMR and whether they can induce platelet activation is not known.</p><p><strong>Methods: </strong>To investigate this, we measured markers of platelet activation (thrombospondin-1 [TSP-1]), mitochondrial-derived N-formyl methionine peptide (fMET), and autoantibodies directed toward specific mitochondrial antigen mitofusin-1 (MFN1) by enzyme-linked immunosorbent assay in plasma of healthy controls (HCs, n = 30) and patients with PMR without giant cell arteritis (GCA) (n = 45) and patients with PMR with GCA (n = 9) before and after treatment with glucocorticoid therapy. Ultrapure mitochondria were opsonized with plasma from patients with PMR without GCA (n = 45) or HCs (n = 10) and were subsequently incubated with HC platelets. Platelet activation was assessed by P-selectin levels using flow cytometry.</p><p><strong>Results: </strong>Plasma levels of anti-MFN1 IgG were elevated in patients with PMR with and without GCA before glucocorticoid therapy when compared with HCs (P < 0.01 for both groups). Levels of anti-MFN1 IgG significantly reduced after treatment with glucocorticoids in both groups (P < 0.01). Levels of fMET were also significantly higher in patients with PMR with and without GCA before glucocorticoid therapy in comparison with HCs (P < 0.001 and P < 0.01, respectively). However, the levels of fMET only dropped significantly after therapy in patients with PMR without GCA (P < 0.001). Plasma levels of TSP-1 were elevated in patients with PMR with and without GCA before glucocorticoid therapy when compared to HC (P < 0.001 for both groups). After glucocorticoid therapy, plasma levels of TSP-1 decreased significantly only in patients with PMR without GCA (P = 0.023). Mitochondria opsonized with plasma from patients with PMR without GCA induced higher platelet activation regardless of treatment status as compared with plasma from HCs (P < 0.0001 and P < 0.01 for pretreatment and posttreatment).</p><p><strong>Conclusion: </strong>Our results indicate increased platelet activation and the presence of mitochondrial antigens and antibodies in the circulation of patients with PMR. Blocking mitochondrial-mediated platelet activation may reduce inflammation in patients with PMR, with potential therapeutic implications.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 3","pages":"e70021"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}